We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead.
- Authors
Satapathy, Swayamjeet; Bal, Chandrasekhar
- Abstract
Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC), though uncommon, presents a considerable therapeutic challenge with poor long-term outcomes. Currently, tyrosine kinase inhibitors are the mainstay of treatment for advanced RAIRDTC patients. However, these agents are associated with a multitude of adverse events with resultant deterioration in the quality-of-life of the patients. Targeted theranostic approaches with radiolabelled integrin binders and fibroblast activation protein- (FAP)- inhibitors seem to have a promising role in the management of such patients. This minireview focuses on these novel theranostic strategies in RAIR-DTC, with emphasis on recent advances, existing challenges, and future directions.
- Subjects
THYROID cancer; PROTEIN-tyrosine kinase inhibitors; INTEGRINS; CLINICAL deterioration
- Publication
Frontiers in Endocrinology, 2022, Vol 13, p1
- ISSN
1664-2392
- Publication type
Article
- DOI
10.3389/fendo.2022.924841